A randomized controlled phase IB trial of the malaria vaccine candidate GMZ2 in african children

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Bélard, Sabine ^a,g   Issifou, Saadou ^a   Hounkpatin, Aurore B ^a   Schaumburg, Frieder ^a,h   Ngoa, Ulysse Ateba ^a   Esen, Meral ^a,b   Fendel, Rolf ^a,b   de Salazar, Pablo Martinez ^a   Mürbeth, Raymund E ^a   Milligan, Paul ^c   Imbault, Nathalie ^d,i   Imoukhuede, Egeruan Babatunde ^d   Theisen, Michael ^e   Jepsen, Søren ^d   Noor, Ramadhani A ^f   Okech, Brenda ^f   Kremsner, Peter G ^a,b   Mordmüller, Benjamin ^a,b  

^a ALBERT SCHWEITZER HOSPITAL   (Gabon)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d STATENS SERUM INSTITUT   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f African Malaria Network Trust   (Tanzania)

^g UNIVERSITY OF FREIBURG   (Germany)

^h UNIVERSITY HOSPITAL MÜNSTER   (Germany)

ⁱ UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FUSION PROTEIN GMZ2 VACCINE; GLUTAMATE RICH PROTEIN; HYDROGEN PEROXIDE; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 3; PARASITE ANTIGEN; RABIES VACCINE; UNCLASSIFIED DRUG; GLUTAMATE RICH PROTEIN, PLASMODIUM; GLUTAMATE-RICH PROTEIN, PLASMODIUM; HYBRID PROTEIN; MEROZOITE SURFACE PROTEIN 3, PLASMODIUM; PROTOZOAL PROTEIN;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ETHNIC GROUP; FEMALE; GABONESE; GEOMETRY; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; LOW DRUG DOSE; MALARIA; MALE; MEMORY CELL; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; AFRICA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALARIA FALCIPARUM; METABOLISM; PHASE 1 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; TREATMENT OUTCOME;

PLASMODIUM FALCIPARUM;

AFRICA; ANTIGENS, PROTOZOAN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 79960872123     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022525     Document Type: Article

References (21)

1. World Health Organisation World Malaria Report 2010 Geneva WHO.
2. Feachem RG, Phillips AA, Hwang J, Cotter C, Wielgosz B, et al. (2010) Shrinking the malaria map: progress and prospects. Lancet 376: 1566-1578.
3. Ballou WR, (2009) The development of the RTS,S malaria vaccine candidate: challenges and lessons. Parasite Immunol 31: 492-500.
4. Cohen S, Mc GI, Carrington S, (1961) Gamma-globulin and acquired immunity to human malaria. Nature 192: 733-737.
5. Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H, et al. (1991) Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 45: 297-308.
6. Sotiriades, (1917) Attempts at serotherapy in malaria. Greek Med 19: 27-28.
7. Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, Bottius E, Kaidoh T, et al. (1994) Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 84: 1594-1602.
8. Meraldi V, Nebie I, Tiono AB, Diallo D, Sanogo E, et al. (2004) Natural antibody response to Plasmodium falciparum Exp-1, MSP-3 and GLURP long synthetic peptides and association with protection. Parasite Immunol 26: 265-272.
9. Soe S, Theisen M, Roussilhon C, Aye KS, Druilhe P, (2004) Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. Infect Immun 72: 247-252.
10. Theisen M, Soe S, Oeuvray C, Thomas AW, Vuust J, et al. (1998) The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. Infect Immun 66: 11-17.
11. Carvalho LJ, Alves FA, Bianco C Jr, Oliveira SG, Zanini GM, et al. (2005) Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA720 adjuvants. Clin Diagn Lab Immunol 12: 242-248.
12. Esen M, Kremsner PG, Schleucher R, Gassler M, Imoukhuede EB, et al. (2009) Safety and immunogenicity of GMZ2- a MSP3-GLURP fusion protein malaria vaccine candidate. Vaccine 27: 6862-6868.
13. Mordmüller B, Szywon K, Greutelaers B, Esen M, Mewono L, et al. (2010) Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambarene, Gabon. Vaccine 28: 6698-6703.
14. Wildling E, Winkler S, Kremsner PG, Brandts C, Jenne L, Wernsdorfer WH, (1995) Malaria epidemiology in th eprovince of Moyen Ogoov, Gabon. Trop Med Parasitol 46: 77-82.
15. Miura K, Orcutt AC, Muratova OV, Miller LH, Saul A, et al. (2008) Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine 26: 193-200.
16. Bauer DF, (1972) Constructing confidence sets using rank statistics. Journal of the American Statistical Association 67: 687-690.
17. Gidudua J, Kohla KS, Halperin S, Hammerc SJ, Heath PT, Hennige R, Hoet B, Rothsteing E, Schuindh A, Varricchioi F, Walopj W, (2008) A local reaction at or near injection site: Case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 26: 6800-6813.
18. Sagara I, Dicko A, Ellis RD, Fay MP, Diawara SI, et al. (2009) A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine 27: 3090-3098.
19. Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, et al. (2009) Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS ONE 4: e4708.
20. de Stricker K, Vuust J, Jepsen S, Oeuvray C, Theisen M, (2000) Conservation and heterogeneity of the glutamate-rich protein (GLURP) among field isolates and laboratory lines of Plasmodium falciparum. Mol Biochem Parasitol 111: 123-130.
21. Singh S, Soe S, Weisman S, Barnwell JW, Perignon JL, et al. (2009) A conserved multi-gene family induces cross-reactive antibodies effective in defense against Plasmodium falciparum. PLoS ONE 4: e5410.